KEYTRUDA (pembrolizumab) Prescribing Information [External link]
Lenvatinib Prescribing Information [External link]
KEYTRUDA® (pembrolizumab), in combination with lenvatinib, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.1
Expert on Demand in First-line Advanced Renal Cell Carcinoma (RCC)
The Expert on Demand programme at MSD provides an exciting opportunity for you and your MDT to connect with Experts in advanced RCC at a time that works for you.
How to sign up?
- Choose your module
- Complete the form below to express your interest
- You will be contacted by your local MSD representative to arrange a suitable time and date
Read more about the available modules in advanced RCC below:
Navigating the evolving landscape of first-line advanced RCC: Advocating patient care and outcomes
This module provides an overview of the CLEAR trial and KEYNOTE-B61 studies. We explore who the eligible patient is for these treatment regimens and explore best practice approaches to multidisciplinary decision-making.
Learning objectives:
- To explore recent updates and key findings from the CLEAR study
- To deepen understanding of how to identify optimal treatment regimens tailored to individual patient needs
- To discuss how to leverage real-world data and patient case studies to help inform effective treatment choices
Speakers
Dr Ricky Frazer MBBCH (Hons), MSc (MedEduc), BSc, PgCert (Onc), PgCert (ClinLead), PgCert (AcuteMed) MAcadMEd, MRCP, AFFML
Consultant Medical Oncologist
Velindre Cancer Centre (VCC), Cardiff
Biography
Dr Frazer specialises in renal cancer, skin cancer and acute oncology and is clinical lead for the acute oncology assessment unit at VCC, the immunotherapy toxicity management service and Advanced Cellular Therapies. He is one of the founding members of the UK Renal Oncology Collaborative (UK ROC). He has a strong educational interest and is currently a Royal College of Physicians (RCP) College Tutor and Faculty Lead. He is also an Honorary Lecturer at Cardiff University and is Programme Director for The Postgraduate Diploma and MSc in Medical Oncology validated by the University of Buckingham and GMC accredited. He has completed an MSc in medical education and was awarded the UK Wide Munro Medal by the RCP for excellence and leadership in education. He is Vice President of the National Immuno-Oncology Clinical Network (IOCN) and Co-leads the monthly National Immuno-Oncology Education Forum. In 2023 and in 2024 he was awarded the individual leader of the year for Velindre NHS Trust and the Southeast Wales Immunotherapy Toxicity Team won the award for education, research and innovation and improving patient experience.
Dr Simon Grumett BSc MB ChB MRCP PhD
Consultant Medical Oncologist
University Hospitals Birmingham NHS Trust
Biography
Dr Simon Grumett is a medical oncologist with over 15 years’ experience in treating urological and skin cancers.
He has previously been Clinical Director and Cancer Lead Clinician at the Royal Wolverhampton Hospitals NHS Trust and is presently based at University Hospitals Birmingham NHS Trust where he is the Training Program Director for Medical Oncology in the West Midlands.
He is an Honorary Associate Clinical Professor at the University of Birmingham and has an interest in mindfulness, eastern philosophy and triathlon.
Dr Will Ince
Consultant Oncologist
Addenbrooke’s Hospital, Cambridge
Biography
Dr Ince is a GU oncologist with a particular interest in immunotherapy and clinical trials. He works in one of the UK’s largest tertiary renal cancer units in Cambridge where he is the research lead for uro-oncology in Cambridge. Dr Ince is the Principal Investigator and Chief Investigator on national and international clinical trials and has been involved with many of the seminal practice changing phase 3 trials, both industry and investigator led. He is a regular invited speaker for symposia and conferences and has co-authored national guidance in kidney cancer.
Identifying and managing IO + TKI adverse events in patients treated with pembrolizumab plus lenvatinib: A multidisciplinary approach, including case studies
This module focuses on adverse event management for patients on combination treatment with pembrolizumab and lenvatinib through interactive case studies
Learning Objectives:
- Gain understanding of the potential adverse events to expect following treatment with pembrolizumab and lenvatinib in first-line advanced RCC
- Join the experts in discussing interactive case studies that explore multidisciplinary approaches to managing toxicity challenges and long-term treatment strategies
This module is not meant to replace the SmPC. Always consult the SmPC for full safety information
Speakers
Professor Agnieszka Michael MRCP PhD
Consultant Medical Oncologist
Royal Surrey NHS Foundation Trust
Biography
Professor Agnieszka Michael is a Clinical Academic at the University of Surrey and a Consultant Medical Oncologist at the Royal Surrey NHS Foundation Trust . She has an interest in ovarian cancer and urological malignancies and immunotherapy. She was awarded a PhD for research in Cancer Immunotherapy by St George’s, University of London, and continues to contribute to this field of research. Throughout her career Professor Michael has worked in the cancer clinical trials’ field, including early phase studies with immunotherapy agents, gene therapy and cancer vaccines as well as international multi-centre phase III and IV studies, as a Chief investigator and a local Principal Investigator. Professor Michael is a Clinical Lead for National Ovarian Cancer Audit, as well as a Chair of Non-surgical Oncology in British Gynaecological Cancer Society. She also worked as a Director of Surrey Clinical Trials’ Unit and Cancer Specialty Lead for NCRN Clinical Research Network, as well as clinical expert for NICE.
Dr Anna Olsson-Brown
Consultant Medical Oncologist
Biography
Anna Olsson-Brown is a Consultant in Medical Oncology. She specialises in the systemic treatment of skin cancers; immunotherapeutic toxicities, early phase/translational clinical trials and acute oncology. She is the Clinical Director for Clinical Cancer Services at Sussex Cancer Centre and an Honorary Senior Lecturer at the University of Liverpool. She has a background in clinical pharmacology and an interest in acute oncology and supportive care for cancer patients particularly with regards to toxicity of cancer therapies. She was an MRC research fellow completing her PhD investigating the mechanisms of immunotherapy toxicity and has subsequently published extensively in the area. She established and led a pan-tumour, pan-regional immunotherapy toxicity service supporting inpatients and outpatients with immunotherapy toxicities prior to her move to Sussex and now leads the service there. She is the current immunotherapy toxicity work stream lead for the NIHR Oncology Translational Research Committee (O-TRC) and a board member of UKASC. She is a founding member and current CEO of the National Immunotherapy Clinical Network (IOCN) and sits on the UK SACT Board within this role. She is a current Oncology representative of the Symposium Committee at the Royal College of Physicians of Edinburgh, representative on the Association of Cancer Physicians and RCPE new consultant committees and senior advisor to the National Oncology Collaboration for Trainee Research (NOTCH).
Trudy Guinan
Nurse Consultant in Immuno-Oncology
The Clatterbridge Cancer Centre
Biography
Trudy Guinan has worked in the field of Oncology for over 20 years, working at The Clatterbridge Cancer Research Centre as an Advanced Nurse Practitioner and Lead Immunotherapy Nurse. During the past 5 years she has worked with Medical Oncologist Dr. Anna Olsson-Brown setting up the UK’s first Immuno-Oncology service at the Cancer Centre, this service has received national recognition (Radio Interviews, ITV’s This morning, BBC Northwest piece) and won an award for innovation in the 2020 British Journal of Nursing (BJN) Awards.
She regularly provides ongoing specialist support and advice to those involved in the delivery of IO across the country, speaks at National conferences and runs a number of Immunotherapy workshops at Clatterbridge for national and international delegates as well as speaking at national conferences.
Trudy has completed her Masters in Advanced Clinical Practice focusing her dissertation on the impact of centralised IO service at The Cancer Centre which was published by BJN in 2020. More recently Trudy has been working with Prof Christian Ottensmeier who has been appointed as Nurse Consultant specialising in Immuno-oncology (the first ever post).
Please refer to the SmPC for further information before making any prescribing decisions.
Reference
- KEYTRUDA Summary of Product Characteristics
Supporting Documentation
KEYTRUDA (pembrolizumab) Prescribing Information [External link]
Lenvatinib Prescribing Information [External link]
To register your interest in Expert on Demand please complete the form below:
